GlycoMimetics (NASDAQ:GLYC) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of GlycoMimetics (NASDAQ:GLYC) in a research report issued on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

GlycoMimetics Trading Up 0.1 %

Shares of GLYC opened at $0.25 on Wednesday. GlycoMimetics has a 52-week low of $0.14 and a 52-week high of $3.53. The company has a 50-day simple moving average of $0.31 and a 200-day simple moving average of $0.24.

Institutional Investors Weigh In On GlycoMimetics

An institutional investor recently raised its position in GlycoMimetics stock. Acadian Asset Management LLC increased its position in shares of GlycoMimetics, Inc. (NASDAQ:GLYC) by 61.8% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 534,753 shares of the biotechnology company’s stock after purchasing an additional 204,227 shares during the quarter. Acadian Asset Management LLC owned 0.83% of GlycoMimetics worth $150,000 as of its most recent filing with the SEC. Institutional investors own 75.19% of the company’s stock.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.